Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation.
暂无分享,去创建一个
T. Panzarella | T. Panzarella | M. Crump | J. Kuruvilla | A. Keating | D. Villa | B. Feng
[1] R. Gascoyne,et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Friedberg,et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era , 2012, Leukemia & lymphoma.
[3] F. Cavalli,et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma , 2012, British journal of haematology.
[4] J. Delabie,et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B‐cell non‐Hodgkin lymphomas. A Norwegian multi centre phase II study , 2011, British journal of haematology.
[5] Andrew Lister,et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.
[6] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] E. Kimby,et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Gascoyne,et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] J. Rossi,et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.
[10] R. Gascoyne,et al. Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma , 2008 .
[11] Randy D Gascoyne,et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[13] R. Gascoyne,et al. Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma. , 2007 .
[14] H. Atkins,et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] C. Akin. What does a basophil do , 2007 .
[16] M. Calaminici,et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] T. Ittel,et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Vellenga,et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. , 2006, Blood.
[19] E. Giné,et al. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[22] P. Gimotty,et al. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma , 2005, Bone Marrow Transplantation.
[23] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[24] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] F. Vicini,et al. Accelerated partial breast irradiation as a part of breast conservation therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[27] R. Tsang,et al. Autotransplants for histologically transformed follicular non‐Hodgkin's lymphoma , 2001, British journal of haematology.
[28] N. Schmitz,et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Gribben,et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[30] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Lister,et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] G. Salles,et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] S. Horning,et al. Long-term survival after histologic transformation of low-grade follicular lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] S. Horning. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. , 1993, Seminars in oncology.
[35] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[36] Y. Luo,et al. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation , 2013 .
[37] R. Rosenquist,et al. Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression , 2008 .
[38] Wen-yu Li,et al. CHOP-Like Chemotherapy Plus Rituximab Versus CHOP-Like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma:A Randomised Controlled Trial by the MabThera International Trial (MInT) Group , 2007 .
[39] Horton,et al. Annals of Oncology , 1991, Springer US.